← All trials
NCT06029426
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 20, 2023
- Primary completion
- Dec 31, 2024
- Completion date
- Jul 31, 2025
- First posted
- Sep 8, 2023
- Last posted
- Dec 29, 2023
- Enrollment
- 332
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Neumora Therapeutics, Inc.Lead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.